Dr. Danilo Verge and Dr. David Kendall, both of whom have decades of experience in the global diabetes space, have joined Zealand Pharma.
As Head of Global Medical Affairs at Zealand Pharma, Dr. Danilo Verge will be responsible for all medical activities worldwide related to Zealand Pharma’s metabolic and gastrointestinal franchises including dasiglucagon, glepaglutide and V-Go®. He brings over 20 years of experience from having built and led Medical Affairs functions.
Dr. David Kendall has taken up the position as Senior Global Medical Advisor Metabolism. In this capacity, Dr. Kendall will be responsible for designing and managing the implementation of the Medical product strategy and plan in the Metabolism Therapy Area, as well as representing Zealand Pharma at relevant scientific and medical fora, among other tasks.
Read more in the recently published press release from Zealand Pharma here